PAR Drugs & Chemicals saw revenue rise to ₹103.12 Cr from ₹95.88 Cr.

Par Drugs and Chemicals LimitedPAR · Filed with the exchange

However, increased expenses led to PBT dropping to ₹17.92 Cr (from ₹19.52 Cr) and net profit to ₹13.36 Cr (from ₹14.50 Cr), showing margin moderation.

A strategic transition was also discussed.

Read the original filing(PDF)

No comments yet. Be the first.

More from Par Drugs and Chemicals Limited

All announcements

Others05-09-2026
Copy of Newspaper Publication
Important01-09-2026
Updates
Others22-08-2026
Shareholders meeting
Board Meeting22-08-2026
Outcome of Board Meeting
Others22-08-2026
Appointment
Others22-08-2026
Appointment

Free

Track this company, and every filing it makes

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

Create a free account

No card needed. Takes about a minute.